Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma

P S Thomas, G Heywood

Background: Inhaled tumour necrosis factor alpha (TNFα) has previously been shown to induce airway neutrophilia and increased airway reactivity in normal subjects. It was hypothesised that a similar challenge would increase airway reactivity in those with mild asthma, but that the inflammatory profile may differ.

Methods: Ten mild asthmatic subjects were recruited on the basis of clinical asthma and either a sensitivity to methacholine within the range defined for asthma or a 20% improvement in forced expiratory volume (FEV1) after 200 µg salbutamol. Subjects inhaled either vehicle control or 60 ng recombinant human (rh)TNFα and were studied at baseline, 6, 24, and 48 hours later. Variables included spirometric parameters, methacholine provocative concentration causing a 20% fall in FEV1 (PC20), induced sputum differential cell count, relative sputum level of mRNA of interleukins (IL)-4, IL-5, IL-9, IL-14, IL-15 and TNFα, and the exhaled gaseous markers of inflammation, nitric oxide and carbon monoxide.

Results: PC20 showed an increase in sensitivity after TNFα compared with control (p<0.01). The mean percentage of neutrophils increased at 24–48 hours (24 hour control: 1.1 (95% CI 0.4 to 2.7) v 9.2 (95% CI 3.5 to 14.9), p<0.05), and there was also a rise in eosinophils (p=0.05). Relative levels of sputum mRNA suggested a rise in expression of TNFα, IL-14, and IL-15, but no change in IL-4 and IL-5. Spirometric parameters and exhaled gases showed no significant change.

Conclusion: The increase in airway responsiveness and sputum inflammatory cell influx in response to rhTNFα indicates that TNFα may contribute to the airway inflammation that characterises asthma.

METHODS

The protocol was approved by the committee on ethical procedures in human subjects of the University of New South Wales. Informed consent was obtained from all participants in the trial.
 Spirometry and bronchial responsiveness  
At the same time of day, subjects initially performed baseline spirometric tests according to ATS recommendations using a dry wedge spirometer (Vitalograph; Buckingham, UK) to derive FEV₁ and forced vital capacity (FVC). A standard methacholine (MCh) challenge test was then administered. Briefly, subjects inhaled 0.9% saline five times by slow inspiration from functional residual capacity to total lung capacity over 1 second using a Mefar dosimeter (Mefar, Brescia, Italy) and then held their breath for 6 seconds. FEV₁ was measured 2 minutes later. Doubling concentrations of methacholine from 0.0625 to 128 mg/ml were inhaled until either a 20% fall in FEV₁ occurred or the concentration of 128 mg/ml was reached. Results are expressed as the logarithm of the dose needed to cause a 20% fall in FEV₁ (log PC₂₀). Airway obstruction was reversed by 200 μg inhaled salbutamol.

Sputum induction  
Sputum induction was performed using a method previously described. Briefly, subjects inhaled nebulised 3.5% saline and lavaged orally with water before voluntary coughing every 2.5 minutes until 5 ml sputum was obtained or 20 minutes had elapsed. Sputum was solubilised by incubation with 1 mmo1 dithiobisretol in phosphate buffered saline (PBS) made up to a total volume of 10 ml and incubated for 15 minutes at 37°C. Cells were then washed thrice in PBS, the cell pellet resuspended, and the total number of pulmonary cells was counted by toluidine blue staining using a haemocytometer. A sample of cells from each preparation was mounted on slides, fixed with methanol, and sequentially stained with eosin and methylene blue dyes. A differential cell count was performed by applying standard morphometric criteria to the first 400 identifiable pulmonary cells. Sputum preparation for cytokine analysis was performed as previously described. Briefly, sputum was stored in denaturing solution consisting of guanadinium, sarcosyl, and β-mercaptoethanol.

Cytokine mRNA analysis  
Total RNA was extracted using the acid-guanadinium thiocyanate-phenol-chloroform method. RNA was precipitated with isopropanol in the presence of glycogen, resuspended in denaturing solution, re-precipitated, and washed in ethanol. Adjustments were made to ensure that RNA from an equivalent number of pulmonary cells was used.  
RNase protection assays were performed on sputum specimens according to the manufacturer’s instructions (RibowQuant, Pharmingen, San Diego, CA, USA), and mRNA expression determined for TNFα, IL-2, IL-4, IL-5, IL-9, IL-13, IL-14, IL-15, and interferon (IFN)-γ. Briefly, sample RNA was hybridised to the α-32P dUTP-labelled hCK-1 probe set and the single stranded RNA digested with a RNase A/T1 mixture before purification and electrophoretically size separated on a 5% polyacrylamide gel (PAGE). The dried gel was subjected to densitometry and phosphorimagery analysis to evaluate the protected bands. Data were expressed as the ratio derived from cytokine/GAPDH density in each lane for each individual. Positive controls consisted of human RNA for each cytokine and yeast tRNA was a negative control; RNA quality was assessed by PAGE.

Exhaled nitric oxide  
Exhaled nitric oxide (eNO) was measured online using a chemiluminescence analyser (Dasibi, Glendale, CA, USA) adapted for online measurement by the method of Kharitonov et al., which has been verified as uncontaminated by nasal NO and complies with current standards published by the ATS and ERS. Subjects exhaled using a slow vital capacity manoeuvre maintaining a positive oral pressure to exclude nasal contamination, and the mean of three peak plateau readings was taken.

Statistical analysis  
Previous work using the primary end point of change in methacholine log PC₂₀ sensitivity and a standard deviation of 0.22 suggested that a significant change would be detected with eight subjects (α = 0.05, 1–β = 0.8). Data are expressed as mean (95% confidence interval, CI) unless otherwise indicated, while log data are expressed as geometric means. Statistical analysis was performed by repeated measures analysis of variance (ANOVA) for data conforming to the Normal distribution with significant results being further analysed by post hoc Bonferroni corrected t tests for multiple comparisons. The Wilcoxon sign rank test was applied to data with a non-parametric distribution.

RESULTS  
Subjects  
All of the subjects tolerated the procedures without incident, but unfortunately one subject failed to complete one arm of the study despite repeated invitations to return. The data are analysed using the remaining nine subjects.

Spirometry  
There was a small fall in mean FEV₁ from 3.55 l (95% CI 1.82 to 5.28) to 3.50 l (95% CI 1.7 to 5.33) 24 hours after rhTNFα inhalation phase with the saline vehicle phase, there was a significant difference between the two groups. The same subjects showed an increase in sensitivity to methacholine responsiveness comparing the TNFα inhalation phase with the saline vehicle phase, there was a significant difference between the two groups. The same subjects showed an increase in sensitivity to

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age/sex</th>
<th>FEV₁ (% predicted)</th>
<th>Methacholine PC₂₀ (mg/ml)</th>
<th>Atopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>41/M</td>
<td>73.5</td>
<td>4.24</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>35/M</td>
<td>107.1</td>
<td>3.22</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>27/F</td>
<td>103.1</td>
<td>4.70</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>26/F</td>
<td>71.0</td>
<td>0.23</td>
<td>Yes</td>
</tr>
<tr>
<td>5*</td>
<td>25/F</td>
<td>95.8</td>
<td>&gt;16</td>
<td>No</td>
</tr>
<tr>
<td>6*</td>
<td>29/M</td>
<td>99.5</td>
<td>&gt;16</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>38/M</td>
<td>85.7</td>
<td>2.11</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>33/M</td>
<td>91.7</td>
<td>0.93</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>42/M</td>
<td>103.0</td>
<td>3.12</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>28/M</td>
<td>81.5</td>
<td>2.46</td>
<td></td>
</tr>
</tbody>
</table>

* Variation in FEV₁ of >20% and >20% improvement after salbutamol.
methacholine after inhaling rhTNFα, and the difference between the two treatments reached statistical significance at 24 hours, as shown in fig 1 (mean difference 83.2%, 95% CI 33.3 to 133.1, Bonferroni corrected p<0.05). Repeated methacholine challenge led to a decrease in sensitivity during the control arm, as previously observed. 

All subjects achieved a MCh PC20, including the two subjects with a baseline value of >16 mg/ml who required an upper doubling dilution of 128 mg/ml.

Sputum inflammatory differential cell counts
After TNFα inhalation there was a significant increase in the percentage of sputum neutrophils at 24 hours (mean difference 8.1%, 95% CI 3.3 to 9.9, Bonferroni corrected p<0.05), and at 48 hours (mean difference 3.4%, 95% CI 1.7 to 5.0, Bonferroni corrected p<0.02), and an increase also in eosinophils at 24 hours (mean difference 1.5%, 95% CI 1.3 to 1.7, Bonferroni corrected p<0.05) compared with the control arm of the study (fig 2). The maximum increase in both of these inflammatory cells was seen at 24 hours and was beginning to subside by 48 hours. There was a non-significant rise in the percentage of lymphocytes over the same time period. No significant changes were seen in the percentage of columnar cells or total number of macrophages.

Cytokine analysis
Messenger RNA from the sputum at 0, 6, 24 and 48 hours after rhTNFα inhalation showed an increase in IL-14, IL-15, and TNFα message compared with the control arm in the majority of subjects at 6 hours only and, although this did not achieve statistical significance (Wilcoxon sign rank test, data not shown), it would be the expected time at which other mediators would be induced. The remaining cytokines showed no increase in message above baseline.

Exhaled NO and CO
There was a non-significant rise in both eNO and eCO after both control and rhTNFα inhalation. Exhaled NO 24 hours after TNF inhalation, expressed as percentage of baseline, was 110.0% (95% CI 80.0 to 139.9) compared with 109.8% (95% CI 98.7 to 121.8) in controls; after 48 hours the corresponding values were 99.7% (95% CI 52.6 to 146.7) and 101.3% (95% CI 97.8 to 121.8) in controls; after 48 hours the corresponding values were 82.1% (95% CI 54.5 to 109.7) and 109.7% (95% CI 94.2 to 125.2), respectively.

DISCUSSION
TNFα is a multifunctional cytokine with a wide range of activities. It has been implicated in a number of diseases including asthma, rheumatoid arthritis, multiple sclerosis, and other inflammatory disorders. It is implicated in cell death and apoptosis but it is also able to generate a non-cytotoxic inflammatory response in certain situations. It has been shown conclusively to be released immediately from mast cells after encounter with specific allergens, and is therefore implicated in allergic asthma.

TNFα is associated with the local upregulation of the adhesion molecules E-selectin, VCAM-1, and ICAM-1 which are involved in leucocyte migration. Both VCAM-1 and ICAM-1 have been shown to be involved in the transmigration of granulocytes across endothelial cultures in vitro and increased VCAM-1 expression is associated with a preponderance of TNFα in eosinophilic nasal polyps. TNFα appears to exert its effect on the increased migration of eosinophils and neutrophils through these adhesion factors, with increased eosinophil attachment reliant upon α4 integrin binding to the upregulated VCAM-1 expression and migration associated with upregulated ICAM-1 expression, although neutralising experiments have implicated the β3 integrins. TNFα supports GM-CSF mediated eosinophil migration, which is dose dependent for both cytokines, and this migration is inhibited by actinomycin D. Both TNFα and IL-1β increase ICAM-1 expression and antibodies to ICAM-1 inhibit this migration through human umbilical vein endothelial cells (HUVEC), and may therefore act in concert with IL-5 in this regard. In asthma, TNFα is more frequently expressed in the airways than in normal subjects, and in allergic polyposis this increase in TNFα is associated with an increase in VCAM-1 and eosinophilic infiltration. It has become apparent that, although eosinophil migration is classically...
Effects of inhaled TNFα in subjects with mild asthma

thought to depend upon eotaxin, IL-4, IL-5, and GM-CSF, there is evidence now to suggest that TNFα can upregulate cells to express IL-5 and eotaxin. The migration of neutrophils into the airway as demonstrated by these experiments in asthmatic subjects confirms our previous findings in normal non-asthmatic subjects. This sputum neutrophilia is associated with an increase in airway reactivity and these findings would fit the hypothesis that airway inflammation induces increased airway reactivity. Sputum neutrophilia is seen in asthma, particularly fatal asthma, although it is recognised less often than the association of asthma with sputum eosinophilia. Sputum neutrophilia could be the result of TNFα release from allergen activated mast cells and macrophages, or via bacterial activation. It is now apparent that both neutrophils and eosinophils are associated with the late phase of the allergic response. Neutrophils are associated in asthma with increased migratory responses, superoxide generation, and increased bronchial ring contractility.

Induced sputum mRNA suggested an increase in message for TNFα, IL-14, and IL-15. The roles of IL-14 and IL-15 have not yet been clarified in asthma, but it is becoming apparent that IL-15 has potent growth factor activity for mast cells in vitro and thus may be a mechanism for perpetuating the allergic inflammatory response. The finding that sputum TNFα mRNA was increased after TNFα exposure was unexpected as a negative feedback mechanism might have been anticipated. It is possible that, on exposure to a low dose of rTNFα, there is an initial amplification of activation before inhibitory mechanisms come into play. It was likewise anticipated that IL-5 would be upregulated by the nebulised TNFα as it has been shown to upregulate IL-5 and downregulate TNFα. Neither change was seen but, again, it is difficult to know whether the local dose delivered in this study would have been comparable to other reports. The dose of rTNFα used was, however, comparable to previous reports of total TNF isolated from BAL fluid after allergen challenge.

Exhaled gas analysis failed to show any significant changes. This may have been because of the small number of study subjects, and there are no data in the literature to suggest an appropriate sample size but, importantly, it also could have been masked by sputum induction. Sputum induction by itself will generate a neutrophil sputum leukocytosis at about 24 hours and this may be the mechanism whereby a slight increase in eNO and eCO is seen in this arm of the study. To show a separate effect of induced rTNFα alone would require a different study design without the induction of sputum. TNFα has been described as upregulating inducible NO synthase and it would be expected that this might be reflected in an increase in eNO, but possibly a larger dose of nebulised TNFα would be required to demonstrate this effect.

In conclusion, it appears that small quantities of cytokines such as TNFα can have proinflammatory effects that are measurable in the airways of subjects with mild asthma. While glucocorticosteroids are the most effective means of inhibiting this inflammation, it is possible that, by inhibiting these cytokines directly, a reduction in airway inflammation and reactivity may be achieved and could be a useful method of reducing exposure to glucocorticosteroids.

ACKNOWLEDGEMENTS

This study was funded by the NH&MRC, Australia. The authors thank the subjects for donating their time.

References

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence based journal available worldwide both as a paper version and on the internet. Clinical Evidence urgently needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence based medicine and the ability to write in a concise and structured way.

We are presently interested in finding contributors with an interest in the following clinical areas:

- Angina pectoris
- Attention deficit hyperactivity disorder
- Genital warts
- Hepatitis B
- Hepatitis C
- HIV
- Influenza
- Varicose veins

Being a contributor involves:

- Appraising the results of literature searches (performed by our Information Specialists) to identify high quality evidence for inclusion in the journal.
- Writing to a highly structured template (about 1500–3000 words), using evidence from selected studies, within 6–8 weeks of receiving the literature search results.
- Working with Clinical Evidence Editors to ensure that the text meets rigorous epidemiological and style standards.
- Updating the text every eight months to incorporate new evidence.
- Expanding the topic to include new questions once every eight months to incorporate new evidence.
- Expanding the topic to include new questions once every 12–18 months.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves, please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Polly Brown (pbrown@bmjgroup.com).